Highlights Laboratorios Farmaceuticos Rovi, S.A. OTC Markets

Stocks

LABFF

ES0157261019

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 11:50:50 2024-11-25 EST			5-day change	1st Jan Change
65.86 ^USD	-27.31%		-.--%	-

07-23	Laboratorios Farmaceuticos Rovi, S.A., H1 2026 Earnings Call, Jul 23, 2026
07-23	Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Half Year Ended June 30, 2026	CI

Highlights

07-23	Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
05-06	Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-06	Laboratorios Farmaceuticos Rovi, S.A. Updates Earnings Guidance for the Full Year 2026	CI
05-06	Rovi Q1 net profit at 9.4 mln euros	RE
05-06	Rovi expects risperidone to reach potential sales of 100-200 mln euros globally over next few years	RE
04-01	Rovi closes deal to buy pharmaceutical manufacturing facility in US	RE
02-25	Pharmaceutical Company Rovi Increases Net Profit Thanks to Okedi and Heparin Sales	RE
02-25	Drugmaker Rovi's net profit rises on higher Okedi, heparin sales	RE
02-25	Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-25	Laboratorios Farmaceuticos Rovi, S.A. Provides Earnings Guidance for the Fiscal Year 2026	CI
02-25	ROVI Proposes Dividend Distribution for the Year 2025	CI
02-25	Rovi to propose dividend of 0.9594 eur/shr	RE
02-25	Rovi FY Ebitda 216.2 mln euros	RE
02-25	Rovi FY net profit at 140.4 mln euros	RE
11-18	Rovi and Roche sign final agreement for manufacture of new medicine	RE
11-06	Rovi sees 2026 operating revenue to increase by up to low double-digit percentage vs 2025	RE
11-05	Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
25-09-29	Rovi's subsidiary buys injectable drug product manufacturing site in Phoenix, Arizona	RE
25-07-24	Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-07-24	Laboratorios Farmaceuticos Rovi, S.A. Reiterates Earnings Guidance for 2025	CI
25-07-24	Rovi sees 2025 operating revenue to decrease by a mid-single-digit percentage versus 2024	RE
25-07-24	Rovi H1 net profit at 39.7 mln euros	RE
25-05-08	Laboratorios Farmacéuticos Rovi Gets EUR36 Million EU Grant for R&D Project	MT
25-05-08	Rovi To Receive 36.3 Mln Euro Grant For Research Into Prolonged-Release Drugs And New Sterile Filling Technologies	RE
25-05-08	Rovi Sees 2025 Operating Revenue To Decrease By Mid-Single-Digit Percentage Vs 2024	RE